Rxivist logo

Ivermectin converts cold tumors hot and synergies with immune checkpoint blockade for treatment of breast cancer

By Dobrin Draganov, Zhen Han, Nitasha Bennett, Darrell Irvine, Peter P Lee

Posted 24 Aug 2020
bioRxiv DOI: 10.1101/2020.08.21.261511

We show that treatment with the FDA-approved anti-parasitic drug ivermectin induces immunogenic cancer cell death (ICD) and robust T cell infiltration into breast tumors. As an allosteric modulator of the ATP/P2X4/P2X7 axis which operates in both cancer and immune cells, ivermectin also selectively targets immunosuppressive populations including myeloid cells and Tregs, resulting in enhanced Teff/Tregs ratio. While neither agent alone showed efficacy in vivo, combination therapy with ivermectin and checkpoint inhibitor anti-PD1 antibody achieved synergy in limiting tumor growth (p=0.03) and promoted complete responses (p<0.01), also leading to immunity against contralateral re-challenge with demonstrated anti-tumor immune responses. Going beyond primary tumors, this combination achieved significant reduction in relapse after neoadjuvant (p=0.03) and adjuvant treatment (p<0.001), and potential cures in metastatic disease (p<0.001). Statistical modeling confirmed bona fide synergistic activity in both the adjuvant (p=0.007) and metastatic settings (p<0.001). Ivermectin has dual immunomodulatory and ICD-inducing effects in breast cancer, converting cold tumors hot, thus represents a rational mechanistic partner with checkpoint blockade. ### Competing Interest Statement The authors have declared no competing interest.

Download data

  • Downloaded 890 times
  • Download rankings, all-time:
    • Site-wide: 35,103
    • In immunology: 1,160
  • Year to date:
    • Site-wide: 92,136
  • Since beginning of last month:
    • Site-wide: 129,888

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide